OrthoPediatrics Corp.
HealthcareNASDAQ:KIDS · NASDAQ Global Market
-$0.01 today
Vol 0.09M · Avg 0.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.4%
avg -24.6%
ROIC
-6.3%
avg -9.8%
ROA
-7.8%
avg -10.1%
Analysis
ROIC is currently the strongest return metric at -6.3% versus its period average of -9.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David R. Bailey | President, Chief Executive Officer & Director | $886,281.00 | — | 47 | $44,384.00 | 0.17% |
Fred L. Hite | Chief Financial Officer, Principal Financial & Accounting Officer, Chief Operating Officer and Director | $808,569.00 | — | 58 | $277,477.00 | 1.08% |
Joseph W. Hauser | President of Trauma, Deformity Correction & OPSB | $666,463.00 | — | 44 | $194,767.00 | 0.76% |
Gregory A. Odle | President of Scoliosis | $525,757.00 | — | 56 | $187,735.00 | 0.73% |
Daniel J. Gerritzen | Executive Vice President of Legal, General Counsel & Secretary | $524,637.00 | — | 56 | $147,054.00 | 0.57% |
Mark C. Throdahl | Executive Chairman | $27,500.00 | — | 75 | $179,317.00 | 0.70% |
Kevin L. Unger MBA/MSHA | President of Enabling Technologies | $22,500.00 | — | 54 | $7,291.00 | 0.03% |
Mark Karshner | Senior Vice President of International Sales | — | — | — | $179,317.00 | 0.70% |
Ray Garrison | Senior Vice President of Quality & Regulatory and Clinical | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$98,525.16
Sells
5
$1.00M
Net Sentiment
$904,924.59
Net selling
Most Active
Hite Fred
2 transactions
Analysis
Insiders reported 1 buys worth $98,525.16 and 5 sells worth $1.00M over the last 12 months. That adds up to net selling of $904,924.59. Hite Fred was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +22.9% | +17.8% (12yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.9% over three years. Forward estimates point to Revenue at +17.8% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Surmodics, Inc.
SRDX
$614.51M
Bioventus Inc.
NASDAQ:BVS
$576.54M
The Oncology Institute, Inc.
NASDAQ:TOI
$530.91M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Semler Scientific, Inc.
SMLR
$310.75M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
RxSight, Inc.
NASDAQ:RXST
$194.98M
Who manages KIDS?
OrthoPediatrics Corp. (KIDS) lists 9 active executives. The top listed executive is Joseph W. Hauser, President of Trauma, Deformity Correction & OPSB.
Are KIDS insiders buying or selling?
Recent insider activity shows net buying of $243.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.